Search

Your search keyword '"Galgani, Simonetta"' showing total 175 results

Search Constraints

Start Over You searched for: Author "Galgani, Simonetta" Remove constraint Author: "Galgani, Simonetta"
175 results on '"Galgani, Simonetta"'

Search Results

1. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study

4. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study

5. Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register

6. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

7. Estimating the Prevalence of Cognitive Impairment and Its Associated Factors in Albania: A Nationwide Cross-Sectional Study.

8. Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination.

10. Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register

11. Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study

12. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

13. Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose

14. Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis

15. Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies

16. Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study

17. Relapse‐associated worsening in a real‐life multiple sclerosis cohort: the role of age and pyramidal phenotype.

19. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis

21. Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies.

23. Zika virus infection in the central nervous system and female genital tract

25. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis

26. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment

27. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: Results from an urban observational cohort

28. Scoring the 10‐year risk of ambulatory disability in multiple sclerosis: the RoAD score

29. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

30. Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years

32. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis

33. Additional file 4 of Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-β therapy of multiple sclerosis patients

34. Additional file 5 of Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-β therapy of multiple sclerosis patients

35. Additional file 3 of Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-β therapy of multiple sclerosis patients

36. MSJ964778_Appendix – Supplemental material for Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression

37. Additional file 6 of Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-β therapy of multiple sclerosis patients

38. Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression.

40. Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis

41. Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study

42. The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)

43. Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.

45. Fingolimod vs dimethyl fumarate in multiple sclerosis

46. Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-β therapy of multiple sclerosis patients.

47. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

49. Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy

50. Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis

Catalog

Books, media, physical & digital resources